Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) is a pioneering biotechnology company that focuses on discovering, developing, and commercializing novel gene and cell therapies, as well as vaccines aimed at improving health and offering hope to patients worldwide. The company's innovative efforts are concentrated on addressing rare and underserved ocular disorders.
Ocugen's core business revolves around a robust clinical pipeline which includes:
- OCU400: A groundbreaking gene-agnostic modifier gene therapy for retinitis pigmentosa (RP), currently in Phase 3 clinical trials. It leverages the nuclear hormone receptor gene NR2E3 to reset altered cellular gene networks and improve retinal health.
- OCU410: A potential one-time gene therapy for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). This therapy targets multiple pathways involved in the disease, including lipid metabolism, inflammation, oxidative stress, and the complement system.
- OCU410ST: Another modifier gene therapy in Phase 1/2 clinical trials for Stargardt disease, the most common form of inherited macular degeneration. It utilizes the AAV delivery platform for the RORA gene to regulate pathways linked to the disease.
Recent milestones include positive feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the OCU400 Phase 3 liMeliGhT clinical trial, as well as the inclusion of Ocugen in the Russell 3000® Index, highlighting its market presence and growth potential.
Ocugen's commitment to innovative therapies is evident through its modifier gene therapy platforms designed to fulfill unmet medical needs related to inherited retinal diseases such as RP, Leber congenital amaurosis, and Stargardt disease. Additionally, the company is advancing research in infectious diseases to bolster public health and orthopedic diseases to meet unmet medical needs.
For the latest updates and detailed information about Ocugen, Inc., visit their official website at www.ocugen.com and follow them on X and LinkedIn.
Ocugen, a biotechnology company, has announced a conference call on August 5, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results. A pre-market earnings announcement will also be issued on that day. Investors can participate via dial-in or webcast. The company is focused on developing novel gene and cell therapies and vaccines, aiming to improve health outcomes globally. Ocugen is advancing a breakthrough therapy platform for retinal diseases and is researching treatments for infectious and orthopedic diseases.
Ocugen announced positive results from a Phase 2/3 pediatric study of COVAXIN™ (BBV152) for COVID-19, demonstrating safety and efficacy in children aged 2-18. The study involved 526 participants who received two doses 28 days apart, showing superior immunogenicity compared to adults. COVAXIN™ is already authorized for emergency use in Mexico for adults, and Ocugen is pursuing pediatric authorization there. The favorable data published in The Lancet Infectious Diseases supports Ocugen’s plans to commercialize COVAXIN™ in North America, catering to demand for traditional vaccines.
Ocugen, a biotechnology company based in Malvern, Pennsylvania, has been recognized by the Philadelphia Business Journal as one of the “2022 Best Places to Work.” This accolade highlights Ocugen's commitment to fostering a positive corporate culture, as determined by employee feedback. Dr. Shankar Musunuri, the CEO, emphasized the importance of this recognition in promoting the company’s mission to innovate health solutions. The awards ceremony for winners in various categories will take place on July 28, 2022.
Ocugen (NASDAQ: OCGN) announced the issuance of U.S. Patent No. 11,351,225 on June 7, 2022, enhancing its gene therapy intellectual property portfolio. This patent covers methods for preventing and treating retinal degenerative diseases, including retinitis pigmentosa and age-related macular degeneration, using specific nuclear hormone receptor genes. The patent, set to expire in March 2034, validates Ocugen's modifier gene therapy platform and strengthens its global patent position.
MALVERN, Pa., June 9, 2022 – Ocugen (NASDAQ: OCGN) announced that Michael Shine, VP of Commercial, will present at the 2022 BIO International Convention in San Diego from June 13-16, 2022. The presentation is set for June 13 at 4:45 p.m. PT, focusing on Ocugen’s clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™, modifier gene therapy programs, and new cell therapy program, NeoCart®. Ocugen aims to develop innovative therapies to address unmet medical needs and improve global health.
Ocugen, Inc. (NASDAQ: OCGN) announced that its NeoCart® therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, aiming to expedite development for knee cartilage repair in adults. This innovative cell therapy, a 3D-engineered cartilage product, could potentially prevent osteoarthritis by rebuilding damaged knee cartilage. Developed originally by Histogenics, NeoCart® represents a significant step in Ocugen's regenerative medicine pipeline as they prepare for Phase 3 clinical trials.
Ocugen announced that Dr. Shankar Musunuri, the company's Chairman and CEO, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET in Miami Beach, Florida. The event focuses on the company's innovative gene therapies and vaccines aimed at improving health outcomes. Interested parties can register to watch the chat virtually. A replay will be available on the Investor’s section of the Ocugen website starting on May 24 for 90 days.
Ocugen, Inc. announces the lifting of the clinical hold by the U.S. FDA on its Phase 2/3 trial for COVAXIN™ (BBV152), a COVID-19 vaccine candidate. Dosing will resume immediately, affirming Ocugen's commitment to providing differentiated vaccine options. The vaccine has been administered over 350 million times globally, approved in India, and authorized in 25 countries. Further emergency use applications are pending in 60 others. Ocugen aims to advance this critical vaccine's development in the U.S., Canada, and Mexico amidst ongoing global demand.
Ocugen, Inc. (NASDAQ: OCGN) reported its first quarter 2022 results, indicating a cash position of $129.9 million, up from $95.1 million in Q4 2021. Significant milestones include the Phase 1/2 trial for OCU400, with the first patient dosed in March and a second in May. The company expanded its COVAXIN™ marketing rights to cover all of North America, including Mexico. R&D expenses rose to $7.9 million from $2.9 million year-over-year. The net loss was $0.09 per share, compared to $0.04 last year. A conference call is scheduled for further discussion.
Ocugen, Inc. (NASDAQ: OCGN) announced a conference call scheduled for May 6, 2022, at 8:30 a.m. ET, to discuss its first quarter 2022 financial results. The company will issue a pre-market earnings announcement on the same day. Investors can join the call via a toll-free dial-in number or through a webcast available on Ocugen's website for approximately 45 days post-call. Ocugen focuses on developing innovative gene therapies and vaccines aimed at addressing unmet medical needs.
FAQ
What is the current stock price of Ocugen (OCGN)?
What is the market cap of Ocugen (OCGN)?
What does Ocugen, Inc. specialize in?
What are Ocugen's key projects?
What recent achievements has Ocugen accomplished?
How does OCU400 work?
What is the significance of Ocugen's modifier gene therapy platform?
What are the target conditions for OCU410?
How does OCU410ST aim to treat Stargardt disease?
What is the impact of Ocugen's inclusion in the Russell 3000® Index?
What steps has Ocugen taken to ensure the success of its clinical therapy programs?
Where can I learn more about Ocugen's latest news and developments?
